Drug Trial Radar · NCT00798317
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Last checked: Nov 20, 2026Latest source record: Dec 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
326
Actual
Start
Dec 2008
Primary completion
Jun 2010
Study completion Jul 2010
Sponsor
- Lead sponsor
- ThromboGenicsIndustry
- Sponsor type
- Industry
- First posted
- Nov 26, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. In previously performed clinical trials, some patients treated with intravitreal microplasmin have had resolution of their underlying condition, including macular hole closure, without need for vitrectomy. This clinical trial is justified because the sponsor believes the potential benefits outweigh the potential risks.
Conditions
- Vitreomacular Adhesion
Interventions
Ocriplasmin 125µgDrug
125µg of ocriplasmin intravitreal injection
PlaceboDrug
Intravitreal injection placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28Time frame: Day 28
Locations
48 sites in 7 countries. Site status is shown where the registry gives one.
Retinal Diagnostic Center
Campbell, California
West Coast Retina Group, Inc
San Francisco, California
California Retina Consultants
Santa Barbara, California
Medeye
Miami, Florida
Retina Specialists
Pensacola, Florida
Paducah Retinal Center
Paducah, Kentucky
Tufts Medical Center
Boston, Massachusetts
Vision Research Center at Truman Medical Center
Kansas City, Missouri
Deleware Valley Retina Associates
Lawrenceville, New Jersey
Capital Region Retina
Albany, New York
Southeast Clinical Research Assoicates, PA
Charlotte, North Carolina
Dean A McGee Eye Institute
Oklahoma City, Oklahoma
Scheie Eye Institute, Penn Eye Care
Philadelphia, Pennsylvania
Black Hils regional Eye Institute
Rapid City, South Dakota
Texas Retina Associates
Arlington, Texas
Retina Research Center
Austin, Texas
Retina Consultants
Fort Worth, Texas
Medical Center Ophthalmology Assoc.
San Antonio, Texas
Eye Care Associates
Tyler, Texas
Vitreoretinal Associates
Seattle, Washington
University Hospital Leuven
Leuven, Belgium
University Hospital Brno
Brno, Czechia
University Hospital Hradec Kralove
Hradec Králové, Czechia
University Hospital Olomouc
Olomouc, Czechia
University Hospital Kralovske Vinohrady
Prague, Czechia
Central Military Hospital
Prague, Czechia
Gemini Eye Clinic
Zlín, Czechia
Augenklinik-Universität Bonn
Bonn, Germany
St. Joseph Stift Bremen Abteilung für Augenheilkunde
Bremen, Germany
Universitäts-Augenklinik Frankfurt am Main
Frankfurt, Germany
Städtische Kliniken Frankfurt am Main, Klinik für Augenheilkunde
Frankfurt am Main, Germany
Universität Göttingen
Göttingen, Germany
Klinik und Poliklinik für Augenheilkunde
Leipzig, Germany
Philipps Universität Marburg
Marburg, Germany
Augenklinik der Ludwig Maximilians Universität München
München, Germany
Augenärzte am St. Franziskus Hospital
Münster, Germany
Augenklinik im Dietrich-
Neubrandenburg, Germany
Indywidualna Specjalistyczna Praktyka Prywatna
Gdansk, Poland
Oddział Okulistyczny OSK,
Katowice, Poland
Instituto Oftalmología de Alicante (Vissum)
Alicante, Spain
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.